Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fluticasone furoate→

Fluticasone furoate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
397864-44-7
PubChem CID
9854489
Molecular formula
C27H29F3O6S
Molecular weight
538.6 g/mol
Drug class
Synthetic glucocorticoidintranasal/inhaled corticosteroid anti-inflammatory agent
Mechanism of action
Activates intracellular glucocorticoid receptors and suppresses inflammatory cytokines and mediator release in airway and nasal tissues. The clinical mechanism depends on the route and whether fluticasone furoate is used alone or in a fixed combination.
Indications / reported uses
  • Treatment of allergic rhinitis symptoms with intranasal fluticasone furoate products
  • Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) only in authorised fixed combinations with a long-acting bronchodilator; fluticasone monotherapy and combination-product indications are not interchangeable

Sources: US DailyMed — Fluticasone furoate nasal spray · US DailyMed — BREO ELLIPTA (fluticasone furoate/vilanterol) · FDA product information

Identification source: PubChem record (CID 9854489). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fluticasone furoate Environmental Risk Assessment (ERA) (the Fluticasone furoate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.